ANG Lifesciences
40.69
-2.14(-5.00%)
Market Cap₹53.11 Cr
PE Ratio-5.04
IndustryHealthcare
Company Performance:
1D-5.00%
1M+40.84%
6M+37.93%
1Y+47.11%
5Y-38.42%
View Company Insightsright
More news about ANG Lifesciences
10Apr 26
ANG Lifesciences India Limited Responds to BSE Query on Recent Price Movement
ANG Lifesciences India Limited has clarified to BSE Limited that recent price movement in its securities is purely market-driven, with no undisclosed price-sensitive information available. The company responded to BSE's April 09, 2026 inquiry, emphasizing its regular compliance with SEBI disclosure requirements and stating it has no control over market-driven price movements.
 no imag found
15Feb 26
ANG Lifesciences Reports Q3 FY26 Financial Results with Detailed Performance Metrics
ANG Lifesciences India Limited reported Q3 FY26 financial results showing revenue growth in standalone operations to ₹2,597.05 lakhs from ₹2,390.85 lakhs year-over-year, though nine-month revenue declined to ₹6,880.44 lakhs from ₹7,224.40 lakhs. The company operates through pharmaceuticals and printing segments with consolidated results approved by the Board on February 14, 2026.
 no imag found
05Feb 26
ANG Lifesciences India Limited Schedules Board Meeting for February 14, 2026 to Consider Q3FY26 Financial Results
ANG Lifesciences India Limited has scheduled a board meeting for February 14, 2026, at 05:00 P.M. to consider and approve unaudited financial results for Q3FY26 and nine months ended December 31, 2025. The meeting will be held at the company's registered office in Amritsar. A trading window closure is in effect from January 1, 2026, until 48 hours after results publication, in compliance with SEBI insider trading regulations.
 no imag found
15Nov 25
ANG Lifesciences Reports Q2 FY2026 Loss, Appoints New Cost Auditor
ANG Lifesciences India Limited reported a reduced net loss of ₹79.98 lakh in Q2 FY2026, down from ₹107.39 lakh in Q2 FY2025. However, revenue from operations decreased to ₹2597.05 lakh from ₹3215.88 lakh year-over-year. For H1 FY2026, the net loss improved to ₹158.71 lakh from ₹383.92 lakh in the previous year. The company's Board approved the appointment of M/s Shreya Sahu & Associates as Cost Auditor for FY2025-26.
 no imag found
ANG Lifesciences
40.69
-2.14
(-5.00%)
1 Year Returns:+47.11%
Industry Peers
Sun Pharmaceutical
1,874.80
(+0.64%)
Divis Laboratories
6,557.50
(-2.32%)
Torrent Pharmaceuticals
4,657.60
(+3.13%)
Cipla
1,454.10
(+0.97%)
Dr Reddys Laboratories
1,375.70
(+1.87%)
Zydus Life Science
1,121.30
(+1.81%)
Lupin
2,409.30
(+2.81%)
Mankind Pharma
2,486.00
(+0.96%)
Aurobindo Pharma
1,547.50
(-0.50%)
Laurus Labs
1,500.30
(+3.47%)